Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vumerity

- PMLiVE

Pfizer gets CHMP backing for leukaemia drug bosutinib

Provides option for patients resistant to tyrosine kinase inhibitors

- PMLiVE

Santhera’s Raxone turned down for rare eye condition

EMA concerned about drug's ability to improve eyesight

- PMLiVE

Biogen Idec, Elan file Tysabri for first-line use

US and EU multiple sclerosis drug submissions follow companion diagnostic approval

- PMLiVE

Biogen submits haemophilia drug for US approval

Step forward for its partnership with Swedish Orphan Biovitrum

- PMLiVE

Biogen Idec drops ALS drug dexpramipexole

Fails to achieve efficacy in phase III trial

- PMLiVE

EMA recommends approval for alcohol dependency drug

Lundbeck’s Selincro to be used in conjunction with psychosocial support

Sanofi reception

Blow for Sanofi as EMA turns down cholesterol drug Kynamro

Points to safety concerns related to liver toxicity and cardiovascular events

- PMLiVE

Roche’s Perjeta backed in EU for breast cancer

CHMP recommends use alongside Herceptin

Novartis building

CHMP backs Novartis’ Bexsero, Exjade

European recommendations for meningitis vaccine and thalassaemia treatment

Sanofi reception

Sanofi’s Lyxumia and Zaltrap backed for European approval

Company on course to expand its diabetes and cancer portfolio

- PMLiVE

Vivus fails to get European backing for obesity treatment Qsiva

EMA raises concerns about drug’s cardiovascular safety

Europe set to approve first Glivec generic

CHMP backs Teva version of Novartis' blockbuster cancer drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links